1887

Abstract

The vaccine effectiveness (VE) of the A/H1N1pdm09 component of the 2017–18 quadrivalent live attenuated influenza vaccine (QLAIV) was improved by performing rational haemagglutinin (HA) mutagenesis. Introducing N125D, D127E, D222G and R223Q substitutions into the HA protein of A/Slovenia/2903/2015 (A/SLOV15) enhanced replicative fitness in primary human nasal epithelial cells (hNECs). This allowed A/SLOV15 to overcome inter-strain competition in QLAIV, resulting in improved VE.

During strain development for the 2021–22 QLAIV formulation, A/H1N1pdm09 LAIV viruses containing wild-type (WT) HA and neuraminidase (NA) sequences were found to replicate poorly in embryonated eggs and hNECs. We aimed to enhance replicative fitness via the HA mutagenesis approach that was performed previously for A/SLOV15. Therefore, combinations of these four mutations were introduced into the HA protein of representative 6B.1A-5a.2 viruses, A/Victoria/2570/2019 and A/Victoria/1/2020 (A/VIC1). Replicative fitness of A/VIC1 V7 was improved ~30-fold in eggs and ~300-fold in hNECs relative to its parent, without compromising other critical LAIV characteristics.

  • This is an open-access article distributed under the terms of the Creative Commons Attribution License.
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001811
2022-11-21
2024-12-09
Loading full text...

Full text loading...

/deliver/fulltext/jgv/103/11/jgv001811.html?itemId=/content/journal/jgv/10.1099/jgv.0.001811&mimeType=html&fmt=ahah

References

  1. World Health Organisation Influenza (seasonal) fact sheet 2018. n.d https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal) accessed 1 November 2021
  2. Centers for Disease Control and Prevention Prevention Strategies for Seasonal Influenza in Healthcare Settings 2021 2021
    [Google Scholar]
  3. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A 2000; 97:6108–6113 [View Article] [PubMed]
    [Google Scholar]
  4. Maassab HF. Adaptation and growth characteristics of influenza virus at 25 degrees c. Nature 1967; 213:612–614 [View Article] [PubMed]
    [Google Scholar]
  5. Jin H, Lu B, Zhou H, Ma C, Zhao J et al. Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60. Virology 2003; 306:18–24 [View Article] [PubMed]
    [Google Scholar]
  6. Chan W, Zhou H, Kemble G, Jin H. The cold adapted and temperature sensitive influenza A/Ann Arbor/6/60 virus, the master donor virus for live attenuated influenza vaccines, has multiple defects in replication at the restrictive temperature. Virology 2008; 380:304–311 [View Article] [PubMed]
    [Google Scholar]
  7. DeBorde DC, Donabedian AM, Herlocher ML, Naeve CW, Maassab HF. Sequence comparison of wild-type and cold-adapted B/Ann Arbor/1/66 influenza virus genes. Virology 1988; 163:429–443 [View Article] [PubMed]
    [Google Scholar]
  8. Chen Z, Aspelund A, Kemble G, Jin H. Genetic mapping of the cold-adapted phenotype of B/Ann Arbor/1/66, the master donor virus for live attenuated influenza vaccines (FluMist). Virology 2006; 345:416–423 [View Article] [PubMed]
    [Google Scholar]
  9. Hoffmann E, Mahmood K, Chen Z, Yang C-F, Spaete J et al. Multiple gene segments control the temperature sensitivity and attenuation phenotypes of ca B/Ann Arbor/1/66. J Virol 2005; 79:11014–11021 [View Article] [PubMed]
    [Google Scholar]
  10. World Health Organisation Recommended composition of influenza virus vaccines for use in the 20202021 northern hemisphere influenza season 2020; 2021 https://cdn.who.int/media/docs/default-source/influenza/who-influenza-recommendations/vcm-northern-hemisphere-recommendation-2020-2021/202002-recommendation.pdf?sfvrsn=6868e7b3_21&download=true
  11. World Health Organisation Recommended composition of influenza virus vaccines for use in the 20212022 northern hemisphere influenza season 2021; 2021 https://cdn.who.int/media/docs/default-source/influenza/who-influenza-recommendations/vcm-northern-hemisphere-recommendation-2021-2022/202102_recommendation.pdf?sfvrsn=2af603d8_12&download=true
  12. McCauley J, Daniels R, Harvey R, Galiano M, Lin YP et al. The Francis Crick Institute Worldwide Influenza Centre report for the WHO annual consultation on the composition of influenza vaccine for the Northern Hemisphere 2022-2023; 2022 https://www.crick.ac.uk/sites/default/files/2022-04/Crick_NH2022-23%20VCM%20report.pdf
  13. Dempsey R, Tamburrino G, Schewe KE, Crowe J, Nuccitelli A et al. Haemagglutinin substitutions N125D, D127E, D222G and R223Q improve replicative fitness and vaccine effectiveness of an A/H1N1pdm09 live attenuated influenza vaccine virus by enhancing α-2,6 receptor binding. PLOS Pathog 2022; 18:e1010585 [View Article] [PubMed]
    [Google Scholar]
  14. Pebody R, Djennad A, Ellis J, Andrews N, Marques DFP et al. End of season influenza vaccine effectiveness in adults and children in the United Kingdom in 2017/18. Euro Surveill 2019; 24:1800488 [View Article]
    [Google Scholar]
  15. Chen Z, Wang W, Zhou H, Suguitan AL Jr, Shambaugh C et al. Generation of live attenuated novel influenza virus A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs. J Virol 2010; 84:44–51 [View Article] [PubMed]
    [Google Scholar]
  16. Hawksworth A, Lockhart R, Crowe J, Maeso R, Ritter L et al. Replication of live attenuated influenza vaccine viruses in human nasal epithelial cells is associated with H1N1 vaccine effectiveness. Vaccine 2020; 38:4209–4218 [View Article] [PubMed]
    [Google Scholar]
  17. Dibben O, Crowe J, Cooper S, Hill L, Schewe KE et al. Defining the root cause of reduced H1N1 live attenuated influenza vaccine effectiveness: low viral fitness leads to inter-strain competition. NPJ Vaccines 2021; 6:35 [View Article] [PubMed]
    [Google Scholar]
  18. Parker L, Ritter L, Wu W, Maeso R, Bright H et al. Haemagglutinin stability was not the primary cause of the reduced effectiveness of live attenuated influenza vaccine against A/H1N1pdm09 viruses in the 2013-2014 and 2015-2016 seasons. Vaccine 2019; 37:4543–4550 [View Article] [PubMed]
    [Google Scholar]
  19. Hoft DF, Babusis E, Worku S, Spencer CT, Lottenbach K et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis 2011; 204:845–853 [View Article] [PubMed]
    [Google Scholar]
  20. Mohn KGI, Smith I, Sjursen H, Cox RJ. Immune responses after live attenuated influenza vaccination. Hum Vaccin Immunother 2018; 14:571–578 [View Article] [PubMed]
    [Google Scholar]
  21. Wang W, Lu J, Cotter CR, Wen K, Jin H et al. Identification of critical residues in the hemagglutinin and neuraminidase of influenza virus H1N1pdm for vaccine virus replication in embryonated chicken eggs. J Virol 2013; 87:4642–4649 [View Article] [PubMed]
    [Google Scholar]
  22. UK Health Security Agency Official Statistics: Surveillance of influenza and other seasonal respiratory viruses in winter 2021 to 2022 2022
    [Google Scholar]
/content/journal/jgv/10.1099/jgv.0.001811
Loading
/content/journal/jgv/10.1099/jgv.0.001811
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error